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by consultant radiologists as ’unsuitable for EVAR’. 66 had OSR and 52 had Pararenal
EVAR (PEVAR).
Results: PEVAR patients were older (74.3yrs vs. 70.8 yrs, p0.014) with higher mean
SVS co-morbidity severity scores (p0.0001). All procedures were within 14 days of
diagnosis. Mean aneurysm diameter was larger in OSR (OSR 6.6cm vs. PEVAR 5.9cm,
p0.010). For PEVAR 83% of endografts were 34mm/36mm. 3-year aneurysm-related
survival was significantly higher with PEVAR (100% vs. OSR (92.4%	/4.37%),
p0.045). PEVAR provided an incremental cost-effectiveness ratio of €129,586 saved
per QALY gained. 3-year freedom from secondary intervention (PEVAR 83.4% vs OSR
95.5%, P0.301) and all-cause survival (PEVAR 57.1% vs. OSR 84.8%, p0.195) were
similar. 30-day morbidity halved with PEVAR (15% vs. 30%, p0.059). Length of
hospital stay (p0.0007) was lower and number of patients fit for discharge to their home
(p0.006) higher with PEVAR.
Conclusions: PEVAR granted our patients longer Q-TWiST and Superior Freedom from
MACE up to three years. Despite 3-year survival rate of 57%, PEVAR is cost-effective
and offered as Endo-bailing for patients living on borrowed time, abolishes the socio-
economic catastrophe of managing a rupture PAAA.
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Background: The risk of clinical apparent, periprocedural stroke after thoracic endovascular
aortic repair (TEVAR) ranges between 2 and 6% and has been associated with increased
postoperative mortality. Stroke after TEVAR is thought to be related to multiple emboli, which
are dislodged during manipulation of guidewires, catheters and large-bore delivery devices in
the diseased aortic arch. Such emboli may also account for clinically silent cerebral ischemia.
However, the rate of silent cerebral ischemia in the setting of TEVAR is yet unknown, but may
be even higher than the rate of clinical apparent neurological events.
Methods: Twenty patients (12 male, 8 female) who underwent TEVAR were included
into this descriptive study; exclusion criteria were a history of stroke, carotid artery
disease, renal failure and contraindications for magnetic resonance imaging (MRI).
Periprocedural apparent and silent cerebral ischemia was assessed by neurological testing
and serial cerebral diffusion-weighted MRI (DW-MRI) at baseline and within the first 10
days (mean: 4.9 days) post procedure.
Results: TEVAR was successful in all patients without immediate clinically apparent
neurological deficits. Post-interventional cerebral DW-MRI detected a total of 33 new foci
of restricted diffusion in 13 of the 20 patients (65%). Lesions were usually multiple (1-6
lesions per patient) and ranged in size between 15 mm3 and 585 mm3. 17 lesions were
found in the left middle cerebral artery and PICA territory, 10 lesions in the right middle
cerebral artery and PICA territory. Overstenting of the left-subclavian artery was
performed in 9 cases, but was not associated with lateralization of lesions. There were no
additional apparent neurological events during the in-hospital period.
Conclusions: TEVAR resulted in a high incidence of new foci of restricted diffusion on
cerebral DW-MRI in a pattern suggestive for periprocedural embolization. Although even
multiple lesions per patients were found, these lesions were not associated with apparent
neurological deficits during the in-hospital period. Further developments in TEVAR
should be directed towards reducing the risk of periprocedural cerebral embolization.
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Background: In the era of drug eluting stent, progression of non-culprit coronary lesion
emerged as a new therapeutic target of coronary artery disease. We aimed to clarify the
prognostic factors for the progression of non-culprit coronary lesion after percutaneous
coronary intervention (PCI).
Methods: We retrospectively examined 401 patients who underwent PCI during
February 2010 to January 2011 in our institute. Among them, 275 patients were
performed follow-up coronary angiography (CAG) 6-12 months after PCI. Patients with
target lesion revascularization (n39) were excluded. Finally, total of 236 patients were
included in this study. Progression of non-culprit lesion was defined as clinically driven
PCI because of the development of coronary lesion which was not significant at initial PCI
but significant at follow-up CAG, and was associated with ischemic symptom and/or
abnormal results of functional study.
Results: Thirty three patients (14%) underwent additional clinically driven PCI to treat
non-culprit coronary lesions. There was no difference in background clinical characteristics
between patient with or without progression of non-culprit lesion PCI. Prevalence of chronic
kidney disease (CKD) (61% vs. 31%, p0.001) and multi-vessel disease (MVD) (55% vs.
35%, p0.027) were significantly higher and statin use (61% vs. 72%, p0.187) was tended
to be lower in patients with non-culprit lesion PCI than those without. Brachial-ankle pulse
wave velocity (baPWV) was significantly higher in patients with non-culprit lesion PCI than
those without (1838371 vs. 1589313cm/s, p0.001). High density lipoprotein cholesterol
level at follow-up CAG was tended to be lower in patients with non-culprit lesion PCI than
those without (5415 vs. 5816mg/dL, p0.147). Multivariate analysis showed that higher
baPWV, CKD, MVD, and lower HDL at follow-up CAG were independent determinants for
progression of non-culprit coronary lesion.
Conclusions: In conclusion, higher baPWV, CKD, MVD, and lower HDL at follow-up
CAG were independent determinants of non-culprit coronary lesion PCI, suggesting
important prognostic role of arterial stiffness and impaired renal function in the
progression of non-culprit coronary artery lesion.
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Background: Recent insurance-based observational data indicate that the ratio of
contrast volume (CV) use to calculated creatinine clearance predicts acute kidney injury
(AKI). Whether these findings will be observed in other populations, is uncertain.
Methods: 11,986 CATH and PCI procedures were performed at a single center (Wake
Forest Baptist Medical Center) between January 2007 and December 2011 and were
evaluated for AKI post-procedure. A contrast minimization strategy including automated
contrast injection was used in all patients. Procedures with missing pre- or post-creatinine
or renal failure with dialysis were excluded (n4,117). Glomerular filtration rate was
estimated (eGFR).
Results: High risk baseline characteristics were significantly more prevalent with AKI
(n430) compared to no AKI (n7,439), including CHF, diabetes, prior renal failure,
acute MI, and elevated baseline creatinine. Per institutional standard of practice CV use
was 20 mL lower per procedure for those with AKI (p0.001), but CV/eGFR was 30%
higher for those with AKI (p0.001). After multivariable adjustment, CV/eGFR
remained a significant independent predictor of AKI, with CV/eGFR 3.0 having 2.18
(1.59-3.00) increased odds of AKI vs. CV/eGFR 3.0 (see Figure).
Conclusions: In this prospective observational registry CV/eGFR was independently
predictive of AKI, with a ratio 3.0 associated with two-fold greater risk of AKI. These
data provide strong support for the use of this metric as a risk-reduction method for AKI
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following CATH and PCI, including settings in which use of contrast-sparing techniques
are standard of practice.
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Background: There is only limited and conflicting information about the impact of
pre-operative chronic kidney disease (CKD) on outcome after transcatheter aortic valve
implantation (TAVI). We sought to evaluate the impact of pre-operative CKD on clinical
outcome after TAVI, with either balloon- or self-expandable prosthesis, using transfemo-
ral or alternative access, in high risk patients with severe aortic stenosis.
Methods: We retrospectively analyzed pooled data from 4 centers’ prospective TAVI
databases (942 patients). VARC endpoint definitions were used. Patients were subdivided
into 4 categories of eGFR to examine the effect of: no ( 90 ml/min/1.73 m2), mild (61
to 90 ml/min/1.73 m2), moderate (31 – 60 ml/min/1.73 m2) and severe ( 30 ml/min/1.73
m2) CKD. To assess the effect of renal function on short- and long-term outcome,
univariable and multivariable logistic regressions were used; no-CKD category was the
reference category.
Results: No CKD was found in 109 patients (11.6%); 330 (35 %) had mild, 400 (42.4
%) moderate and 103 (11%) severe CKD. Baseline and procedural characteristics were
similar among all groups except for the Logistic EuroSCORE, incidence of severe left
ventricular dysfunction, anemia, and a transapical approach, which was higher when the
CKD was more severe. Major stroke (severe CKD: 4.9 %, moderate: 2.8 %, mild: 1.2 %,
no: 1.8 %, p0.05), life-threatening bleeding (severe CKD: 24.3%, moderate 14.8 %,
mild: 11.2 %, no: 8.3 %, p0.001), all-cause 30-day mortality (severe CKD 9.7%,
moderate 8.5%, mild 6.7%, no 1.7%, p0.02) and one-year mortality differed signifi-
cantly across CKD groups. By multivariate analysis, severe CKD (HR 4.21, 95 % CI
1.67-10.66) was an independant predictor of one-year mortality.
Conclusions: Patients with CKD who undergo TAVI have a higher risk profile and a
worse 30-day and one-year outcome. Severe CKD at baseline is an independent predictor
of 1-year mortality after TAVI.
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Background: Diagnosis of acute kidney injury (AKI) relies on a late marker, namely
serum creatinine (SCr). Several biomarkers are considered for an early and sensitive
detection of contrast-induced nephropathy (CIN). In particular, urinary Neutrophil
Gelatinase-Associated Lipocalin (uNGAL) has been used for early detection of AKI in the
emergency department, after cardiopulmonary bypass or following contrast medium
(CM) exposition. Our study was conducted to assess the value of uNGAL as an early
detector of CIN in patients undergoing percutaneous coronary procedures (PCP) and
whether or not uNGAL correlates with the volume of CM.
Methods: We enrolled 244 consecutive patients undergoing PCP with Iomeprolum at our
institution. CIN was defined as a25% increase in SCr from baseline when measured 2-4
days after PCP. uNGAL was measured at its peak (4-6 hours after PCP) with the Abbott
ARCHITECT assay.
Results: Among the patients (median[iqr] age 66.6[59.5-74.7] years, 70% male),
149(61%) underwent a diagnostic PCP and 95(39%) underwent a therapeutic PCP with a
median CM volume of 123[88-168] ml. 25(10%) patients developed CIN after PCP. We
found neither a significant difference in uNGAL levels between patients with and without
CIN (p0.20), nor a significant correlation between the CM volume versus uNGAL
levels (r-0.11) (Fig. 1).
Conclusions: In a large cohort of patients at low-risk for contrast-induced nephropathy,
urinary NGAL measured 4 to 6 hours after PCP was not useful in predicting the
development of contrast-induced nephropathy and did not correlate with the volume of
contrast medium used during the procedure.
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Background: Contrast-induced acute kidney injury (CI-AKI) continues to be an
important complication of contrast administration. We’ve recently discovered the utility
of substituted cyclodextrins (SCD) for mitigating the renal toxicity of several classes of
nephrotoxic agents including antibiotics, anticancer agents and contrast agents (CA). This
discovery is the basis for the development of Veropaque, a new contrast agent containing
iohexol and a SCD. Here we report on preclinical animal studies using several CAs and
SCDs.
Methods: Formulations containing iopamidol, iodixanol and iohexol were prepared
w/wo various amounts of sulfobutylether--cyclodextrin (SBECD) or 2-hydroxypropyl-
-cyclodextrin (HPCD). The formulations were dosed iv at 1.5 g Iodine/kg to renally
compromised (RC) mice and rats. Plasma samples were taken for creatinine analysis, and
kidney pathology was evaluated at 24 or 48h. A 14-day survival study in RC rats was also
conducted with 2.5g I/mL iv doses of iohexol or iohexol	SBECD (Veropaque). The
iohexol and Veropaque formulations were also rapidly injected into the left main coronary
artery of anesthetized instrumented dogs. ECG and hemodynamics were monitored.
Results: Small amounts of SCD added to CA formulations dramatically reduced the
kidney pathology in both rats and mice at 24 and 48h and preserved kidney function as
measured by plasma creatinine. The nephroprotection was observed for both SCDs and all
three CAs and was dose dependent on the SCD from CA:SCD mole ratios of 1:0.0125 to
1:0.05. The SCD also reduced mortality in the 14-day study (8/8 control, 4/8 iohexol, 7/8
Veropaque survived). Intracoronary injections in the dog model revealed no significant
differences between iohexol and Veropaque and no notable effects on most measured
cardiovascular parameters other than transient changes in LV contractility and QTc
interval as previously described in the literature.
Conclusions: SCDs are nephroprotective against CI-AKI pathology, functional changes,
and mortality in rodent models without altering the expected cardiac hemodynamic and
electrophysiologic effects of the CAs. Further development of Veropaque is warranted and
underway.
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Background: Few data are currently available about the characteristics and procedural
features associated with Acute kidney Injury (AKI) after Transcatheter Aortic Valve
Implantation (TAVI) using the new recommended Valve Academic Research Consortium
(VARC) definition.
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